Regional laboratory network for surveillance of invasive fungal infections and antifungal susceptibility in Latin America;Red Regional de Laboratorios para la Vigilancia de las Infecciones Fúngicas Invasoras y Susceptibilidad a los Antifúngicos

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 23, Issue 2, 2008, Pages 129-134

  Cuenca Estrella, Manuel ^a   Rodríguez Tudela, Juan L ^a   Córdoba, Susana ^b   Melhem, Marcia C ^c   Szeszs, María W ^c   Castañeda, Elizabeth ^d   Martínez, Gerardo ^e   Gabastou, Jean Marc ^f  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

^d INSTITUTO NACIONAL DE SALUD   (Colombia)

^e INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^f Unidad de Medicamentos Esenciales   (Ecuador)

Author keywords

Antifungal agents; Diagnosis; Latin America; Mycoses; Pan American Health Organization; Surveillance

Indexed keywords

EPIDEMIOLOGY; FUNGAL DISEASE; IDENTIFICATION METHOD; LABORATORY METHOD; MICROBIOLOGY; PARASITOLOGY;

LATIN AMERICA;

EID: 42149147442     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/s1020-49892008000200014     Document Type: Article

References (32)

1. Cuenca-Estrella M, Rodero L, Garcia-Effron G, Rodriguez-Tudela JL. Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother. 2002;49(6):981-7.
2. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. In vitro activities of ravu-conazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob Agents Chemother. 2004;48(8): 3107-11.
3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133-63.
4. Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev. 1995; 8(4):462-78.
5. Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis. 1996;22 (suppl 2):S112-8.
6. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26(4):781-803.
7. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis. 1999;1(4):247-61.
8. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999; 12(2):310-50.
9. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001;33(10):1692-6.
10. Singh N. Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management. Medical Mycology. 2005;43(suppl l):S267-70.
11. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2005; 43(4):1829-35.
12. Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40(11):1625-34.
13. Guarro J, Kantarcioglu AS, Horre R, Rodriguez-Tudela JL, Cuenca EM, Berenguer J, et al. Scedosporium apio-spermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol. 2006;44(4):295-327.
14. González A, Tobón AM. Infecciones micóticas oportunistas en pacientes con VIH/SIDA. Infectio. 2006;10(4): 279-88.
15. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK, CDC, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR. 2004;53(RR-15): 1-112.
16. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546-54.
17. Gavalda J, Len O, San Juan R, Aguado JM, Fortun J, Lumbreras C, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis. 2005; 41(1): 52-9.
18. Arendrup MC, Fuursted K, Gahrn-Hansen B, Jensen IM, Knudsen JD, Lundgren B, et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol. 2005;43(9):4434-40.
19. Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol. 2005;26(6):540-7.
20. Pinner RW, Rebmann CA, Schuchat A, Hughes JM. Disease surveillance and the academic, clinical, and public health communities. Emerg Infect Dis. 2003; 9(7):781-7.
21. Shetty SS, Harrison LH, Hajjeh RA, Taylor T,"Mirza SA, Schmidt AB, et al. Determining risk factors for candidemia among newborn infants from population-based surveillance: Baltimore, Maryland, 1998-2000. Pediatr Infect Dis J. 2005;24(7):601-4.
22. Grigull L, Beier R, Schrauder A, Kirschner P, Loening L, Jack T, et al. Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL. Mycoses. 2003;46 (11-12):441-6.
23. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004; 38(9):1237-42.
24. Castagnola E, Cesaro S, Giacchino M, Livadiotti S, Tucci F, Zanazzo G, et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J. 2006; 25(7):634-9.
25. Cuenca-Estrella M, Rodriguez D, Almirante B, Morgan J, Planes AM, Almela M, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother. 2005; 55(2):194-9.
26. Cuenca-Estrella M, Rodriguez-Tudela JL. Should antifungal treatments be based upon results of antifungal susceptibility testing? Rev Iberoam Micol. 2002;19(3):133-8.
27. Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. Clinical relevance of mechanisms of antifungal drug resistance in filamentous fungi. Enferm In-fecc Microbiol Clin. 2002;20(10):523-9.
28. White TC. Mechanism of resistance to antifungal agents. En: Pfaller MA, ed. Manual of Clinical Microbiology. Washington: ASM Press, 2003. Pp. 1869-79.
29. Clinical Laboratory Standard Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast; Approved Standard-Second Edition. Document M27-A2. Wayne, Pennsylvania, USA; 2002.
30. Cuenca-Estrella M, Moore CB, Barchiesi F, Bille J, Chryssanthou E, Denning DW, et al. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect. 2003;9(6):467-74.
31. Clinical Laboratory Standards Institute. Method for disk diffusion susceptibility testing of yeasts. Approved guideline. Document M44-A. Wayne, Pennsylvania, USA; 2004.
32. Barry AL, Pfaller MA, Brown SD, Espinel-Ingroff A, Ghannoum MA, Knapp C, et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol. 2000;38(9):3457-9.